Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 9/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 9/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2349189 | 0.85 | AKR1C3 (0.43) | — | |
| SCHEMBL900666 | 0.81 | FFAR4 (0.44) | FFAR4FFAR1PDE2APIM1 | |
| SCHEMBL24223658 | 0.81 | FFAR4 (0.44) | FFAR4FFAR1PDE2APIM1 | |
| SCHEMBL5041168 | 0.79 | IDO1 (0.46) | PDE2A | |
| SCHEMBL5041582 | 0.77 | EPHX2 (0.45) | PDE2A | |
| SCHEMBL5041933 | 0.77 | ALDH1A1 (0.38) | — | |
| SCHEMBL20472383 | 0.76 | PDE2A (0.51) | PDE2ARIPK1 | |
| SCHEMBL5041566 | 0.76 | ALDH1A1 (0.50) | — | |
| SCHEMBL17295978 | 0.75 | GPR139 (0.46) | FFAR1 | |
| SCHEMBL29017154 | 0.75 | GPR139 (0.46) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3868758-B1 | THIADIAZOLE DERIVATIVES AND USE THEREOF AS A GLS1 INHIBITORS FOR THE TREATMENT OF CANCER | MEDSHINE DISCOVERY INC (CN) | 2023-01-04 | — | — | EP | disclosed |
| US-11230544-B1 | Substituted 1,3,4-thiadiazoles as GLS1 inhibitors | MEDSHINE DISCOVERY INC. (CN) | 2022-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11230544-B1 | Substituted 1,3,4-thiadiazoles as GLS1 inhibitors | GLS2, GLS, GYS2 | FFAR4 1585/4885FFAR1 1309/4885PDE2A 3095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.